| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1009041579 |
| P356 | DOI | 10.1038/NRC3844 |
| P698 | PubMed publication ID | 25533676 |
| P50 | author | Eamonn R Maher | Q56435841 |
| P2093 | author name string | Tim Eisen | |
| Lucy Gossage | |||
| P2860 | cites work | Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function | Q22009393 |
| The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis | Q22009936 | ||
| HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing | Q24291102 | ||
| A conserved family of prolyl-4-hydroxylases that modify HIF | Q24291794 | ||
| Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling | Q24297062 | ||
| Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL | Q24299061 | ||
| Inhibition of Transcription Elongation by the VHL Tumor Suppressor Protein | Q24336629 | ||
| Binding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C | Q24336712 | ||
| Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma | Q24337664 | ||
| Mutation of the Von Hippel-Lindau tumour suppressor gene in capillary haemangioblastomas of the central nervous system | Q71398598 | ||
| [Results of mutation analyses of von Hippel-Lindau disease gene in Japanese patients: comparison with results in United States and United Kingdom] | Q71549928 | ||
| Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis | Q71634131 | ||
| Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas | Q71678927 | ||
| Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations | Q71729095 | ||
| Frequent overexpression of vascular endothelial growth factor gene in human renal cell carcinoma | Q72522741 | ||
| Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours | Q72679743 | ||
| Analysis of multiple renal cell adenomas and carcinomas suggests allelic loss at 3p21 to be a prerequisite for malignant development | Q73590491 | ||
| Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor | Q74093367 | ||
| Inhibitors of Transcription, Proteasome Inhibitors, and DNA-Damaging Drugs Differentially Affect Feedback of p53 Degradation | Q77403566 | ||
| von Hippel-Lindau tumor suppressor protein represses platelet-derived growth factor B-chain gene expression via the Sp1 binding element in the proximal PDGF-B promoter | Q77986081 | ||
| The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway | Q79286125 | ||
| Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2 | Q80799407 | ||
| Role of elongin-binding domain of von Hippel Lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma | Q81232141 | ||
| Folding and quality control of the VHL tumor suppressor proceed through distinct chaperone pathways | Q81813867 | ||
| Von hippel-lindau disease and erythrocytosis | Q83578987 | ||
| Genotype-phenotype correlations in VHL exon deletions | Q84571474 | ||
| Interplay between HDAC3 and WDR5 is essential for hypoxia-induced epithelial-mesenchymal transition | Q84872949 | ||
| Regulation of Hypoxia-Inducible mRNAs by the von Hippel-Lindau Tumor Suppressor Protein Requires Binding to Complexes Containing Elongins B/C and Cul2 | Q24523680 | ||
| von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination | Q24554216 | ||
| HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation | Q24555773 | ||
| The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins | Q24564802 | ||
| Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein | Q24599442 | ||
| Mutation and cancer: statistical study of retinoblastoma | Q24618185 | ||
| von Hippel-Lindau disease: a clinical and scientific review | Q24622030 | ||
| The Catalogue of Somatic Mutations in Cancer (COSMIC) | Q24653244 | ||
| Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex | Q24654714 | ||
| pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2 | Q24684757 | ||
| Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth | Q24800550 | ||
| Genetic analysis of pathways regulated by the von Hippel-Lindau tumor suppressor in Caenorhabditis elegans | Q24804603 | ||
| HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression | Q27025886 | ||
| Artificial ligand binding within the HIF2 PAS-B domain of the HIF2 transcription factor | Q27653363 | ||
| Allosteric inhibition of hypoxia inducible factor-2 with small molecules | Q27676596 | ||
| Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network | Q27852242 | ||
| Comprehensive molecular characterization of clear cell renal cell carcinoma | Q27852374 | ||
| Integrated molecular analysis of clear-cell renal cell carcinoma | Q27852382 | ||
| The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. | Q27852466 | ||
| Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation | Q27860876 | ||
| Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 | ||
| Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus | Q28242901 | ||
| Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor suppressor protein | Q28246139 | ||
| Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer | Q28267037 | ||
| The concept of synthetic lethality in the context of anticancer therapy | Q28268061 | ||
| Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase | Q28506124 | ||
| pVHL function is essential for endothelial extracellular matrix deposition. | Q28589604 | ||
| HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner | Q28589605 | ||
| Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice | Q28590550 | ||
| Acute postnatal ablation of Hif-2alpha results in anemia | Q28591898 | ||
| Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo | Q28594830 | ||
| Binding of natively unfolded HIF-1alpha ODD domain to p53 | Q28910406 | ||
| Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes | Q29615757 | ||
| Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein | Q29615928 | ||
| Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein | Q29615931 | ||
| High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. | Q36029877 | ||
| von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis | Q36121776 | ||
| A rationally designed small molecule that inhibits the HIF-1alpha-ARNT heterodimer from binding to DNA in vivo | Q36130851 | ||
| Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy | Q36220497 | ||
| A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. | Q36222472 | ||
| Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor | Q36446896 | ||
| The von Hippel-Lindau tumor suppressor protein and Egl-9-Type proline hydroxylases regulate the large subunit of RNA polymerase II in response to oxidative stress | Q36540303 | ||
| Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells | Q36549605 | ||
| The positive regulation of p53 by the tumor suppressor VHL. | Q36592019 | ||
| Molecular pathways in renal cell carcinoma--rationale for targeted treatment | Q36625166 | ||
| Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma | Q36736210 | ||
| The phenotype of polycythemia due to Croatian homozygous VHL (571C>G:H191D) mutation is different from that of Chuvash polycythemia (VHL 598C>T:R200W) | Q36862486 | ||
| Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality | Q36930538 | ||
| Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice | Q36953894 | ||
| Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen | Q36954859 | ||
| Downregulation of integrins by von Hippel-Lindau (VHL) tumor suppressor protein is independent of VHL-directed hypoxia-inducible factor alpha degradation | Q37001497 | ||
| HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma | Q37052897 | ||
| Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis | Q37132758 | ||
| Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products | Q37230912 | ||
| pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development | Q37275211 | ||
| Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene | Q37285776 | ||
| Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein | Q37286026 | ||
| Hypoxia-inducible factor 2 regulates hepatic lipid metabolism | Q37302297 | ||
| Emerging roles of microRNAs in the molecular responses to hypoxia | Q37635252 | ||
| Novel homozygous VHL mutation in exon 2 is associated with congenital polycythemia but not with cancer. | Q37685596 | ||
| Alterations in VHL as potential biomarkers in renal-cell carcinoma | Q37724576 | ||
| Oxygen sensing, homeostasis, and disease | Q37914865 | ||
| Treatment selection in metastatic renal cell carcinoma: expert consensus | Q37999655 | ||
| Generation of a Mouse Model of Von Hippel–Lindau Kidney Disease Leading to Renal Cancers by Expression of a Constitutively Active Mutant of HIF1α | Q39042077 | ||
| The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice. | Q39250750 | ||
| HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5. | Q39252741 | ||
| Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia. | Q39273902 | ||
| The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C. | Q39513689 | ||
| VHL Gene Mutations and Their Effects on Hypoxia Inducible Factor HIFα: Identification of Potential Driver and Passenger Mutations | Q39515837 | ||
| Priming-dependent phosphorylation and regulation of the tumor suppressor pVHL by glycogen synthase kinase 3. | Q34569182 | ||
| Identification and evaluation of soft coral diterpenes as inhibitors of HIF-2α induced gene expression. | Q34700627 | ||
| Von Hippel-Lindau disease in a Newfoundland kindred | Q34726572 | ||
| The von Hippel–Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal | Q34744818 | ||
| The von Hippel-Lindau Tumor Suppressor Protein Is Required for Proper Assembly of an Extracellular Fibronectin Matrix | Q34748818 | ||
| pVHL 19 is a biologically active product of the von Hippel–Lindau gene arising from internal translation initiation | Q34753344 | ||
| Quantitative image analysis identifies pVHL as a key regulator of microtubule dynamic instability | Q35005618 | ||
| Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization | Q35006577 | ||
| Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo | Q35065823 | ||
| A new hypoxia inducible factor-2 inhibitory pyrrolinone alkaloid from roots and stems of Piper sarmentosum. | Q35194070 | ||
| The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity | Q35201819 | ||
| Genetic and Functional Studies Implicate HIF1α as a 14q Kidney Cancer Suppressor Gene | Q35452783 | ||
| Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system | Q35462032 | ||
| Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinase | Q35574224 | ||
| VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail | Q35641669 | ||
| Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma | Q35741707 | ||
| Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. | Q35889809 | ||
| HIF-1 antagonizes p53-mediated apoptosis through a secreted neuronal tyrosinase | Q35893950 | ||
| Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. | Q39700386 | ||
| Software and database for the analysis of mutations in the VHL gene | Q39722266 | ||
| NF-kappaB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas | Q39752810 | ||
| Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells | Q39773550 | ||
| VHL loss causes spindle misorientation and chromosome instability. | Q39822734 | ||
| Regulation of renal epithelial tight junctions by the von Hippel-Lindau tumor suppressor gene involves occludin and claudin 1 and is independent of E-cadherin | Q39906454 | ||
| von Hippel-Lindau tumor suppressor gene-dependent mRNA stabilization of the survival factor parathyroid hormone-related protein in human renal cell carcinoma by the RNA-binding protein HuR. | Q39908665 | ||
| Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1alpha | Q39949245 | ||
| The von Hippel-Lindau Tumor Suppressor Gene Product Interacts with Sp1 To Repress Vascular Endothelial Growth Factor Promoter Activity | Q40023447 | ||
| Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. | Q40127751 | ||
| Interaction of hydroxylated collagen IV with the von hippel-lindau tumor suppressor. | Q40163119 | ||
| Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patients | Q40169023 | ||
| Development of a cell-based reporter assay for screening of inhibitors of hypoxia-inducible factor 2-induced gene expression | Q40252871 | ||
| Primary cilium formation requires von hippel-lindau gene function in renal-derived cells | Q40254089 | ||
| Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway | Q40266970 | ||
| Activation of HIF2α in Kidney Proximal Tubule Cells Causes Abnormal Glycogen Deposition but not Tumorigenesis | Q40321378 | ||
| Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis | Q40322124 | ||
| Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor | Q40396846 | ||
| VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism. | Q40479170 | ||
| Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. | Q40585447 | ||
| Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. | Q40633683 | ||
| Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways | Q40655882 | ||
| An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association | Q40914690 | ||
| Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia | Q41222952 | ||
| Tumour suppression by the human von Hippel-Lindau gene product | Q41320477 | ||
| Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface | Q41857906 | ||
| Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma | Q41919666 | ||
| Renal oxygenation suppresses VHL loss-induced senescence that is caused by increased sensitivity to oxidative stress | Q42413615 | ||
| Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity | Q42469993 | ||
| Genetic basis of congenital erythrocytosis: mutation update and online databases | Q42622691 | ||
| Mutations of the VHL tumour suppressor gene in renal carcinoma | Q42806703 | ||
| Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial | Q42962024 | ||
| The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF. | Q43154570 | ||
| Genetic deletion of the long isoform of the von Hippel-Lindau tumour suppressor gene product alters microtubule dynamics | Q43426283 | ||
| VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. | Q43455466 | ||
| Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. | Q43806776 | ||
| Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions | Q43999004 | ||
| Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein | Q44043145 | ||
| The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma | Q44043146 | ||
| HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron | Q44068443 | ||
| Mutations in the VHL gene in sporadic apparently congenital polycythemia | Q44189671 | ||
| Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions. | Q44230145 | ||
| Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. | Q44247719 | ||
| Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor. | Q44790615 | ||
| Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype | Q44847029 | ||
| Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development. | Q45880509 | ||
| Molecular study of congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less than half of the cases (Where is/are the missing gene(s)?). | Q45897769 | ||
| Exploring the limits of benzimidazole DNA-binding oligomers for the hypoxia inducible factor (HIF) site. | Q45981766 | ||
| Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. | Q46014175 | ||
| Zebrafish mutants in the von Hippel-Lindau tumor suppressor display a hypoxic response and recapitulate key aspects of Chuvash polycythemia | Q46079205 | ||
| Alu-Alu recombination underlies the vast majority of large VHL germline deletions: Molecular characterization and genotype-phenotype correlations in VHL patients | Q46091220 | ||
| von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma | Q46478024 | ||
| Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma | Q46876961 | ||
| Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis | Q47981361 | ||
| Fibronectin is a hypoxia-independent target of the tumor suppressor VHL. | Q48035055 | ||
| Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function | Q48367527 | ||
| Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions. | Q53352910 | ||
| The VHL tumor suppressor: riding tandem with GSK3beta in primary cilium maintenance | Q53536706 | ||
| Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. | Q53623968 | ||
| Über eine sehr seltene Erkrankung der Netzhaut | Q56068022 | ||
| ZUR FRAGE DER ANGIOMATOSIS RETINae UND IHRER HIRNKOMPLIKATIONEN | Q56068023 | ||
| Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma | Q57177515 | ||
| Direct Interaction of the β-Domain of VHL Tumor Suppressor Protein with the Regulatory Domain of Atypical PKC Isotypes | Q58323654 | ||
| Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma | Q59077568 | ||
| Specific genetic change in tumors associated with von Hippel-Lindau disease | Q69641054 | ||
| Identification of the von Hippel-Lindau disease tumor suppressor gene | Q29618644 | ||
| Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation | Q29619687 | ||
| Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC | Q29937783 | ||
| Genotype-phenotype correlations in von Hippel-Lindau disease. | Q30357251 | ||
| Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency | Q30465158 | ||
| The von Hippel-Lindau tumor suppressor protein controls ciliogenesis by orienting microtubule growth | Q30480543 | ||
| Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing | Q33396143 | ||
| Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma | Q33473894 | ||
| Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma | Q33597694 | ||
| Von Hippel-Lindau (VHL) disease: distinct phenotypes suggest more than one mutant allele at the VHL locus | Q33641198 | ||
| A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy | Q33642615 | ||
| Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas | Q33682913 | ||
| Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant protein | Q33719533 | ||
| Molecular genetics of clear-cell renal cell carcinoma | Q33729097 | ||
| Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. | Q33863055 | ||
| Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer | Q33865946 | ||
| Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC. | Q33886538 | ||
| Function in protein folding of TRiC, a cytosolic ring complex containing TCP-1 and structurally related subunits | Q33938572 | ||
| Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. | Q33945016 | ||
| Genetic analysis of von Hippel-Lindau disease. | Q34098432 | ||
| Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia | Q34157665 | ||
| Agents That Stabilize Mutated von Hippel–Lindau (VHL) Protein: Results of a High-Throughput Screen to Identify Compounds That Modulate VHL Proteostasis | Q34167307 | ||
| BAP1 loss defines a new class of renal cell carcinoma | Q34280223 | ||
| Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. | Q34286240 | ||
| Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma | Q34320299 | ||
| An Analysis of Phenotypic Variation in the Familial Cancer Syndrome von Hippel–Lindau Disease: Evidence for Modifier Effects | Q34387297 | ||
| Lack of a Functional VHL Gene Product Sensitizes Renal Cell Carcinoma Cells to the Apoptotic Effects of the Protein Synthesis Inhibitor Verrucarin A | Q34404515 | ||
| von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. | Q34514928 | ||
| Germ-line mutations in nonsyndromic pheochromocytoma | Q34523021 | ||
| VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. | Q34523542 | ||
| Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. | Q34524947 | ||
| Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. | Q34530199 | ||
| Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells | Q34536583 | ||
| LINDAU'S DISEASE. REVIEW OF THE LITERATURE AND STUDY OF A LARGE KINDRED. | Q34540867 | ||
| p53 stabilization and transactivation by a von Hippel-Lindau protein | Q34567288 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 55-64 | |
| P577 | publication date | 2015-01-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Nature Reviews Cancer | Q641657 |
| P1476 | title | VHL, the story of a tumour suppressor gene | |
| P478 | volume | 15 |
| Q64890149 | A Human Adult Stem Cell Signature Marks Aggressive Variants across Epithelial Cancers. |
| Q47208178 | A New Perspective on the Heterogeneity of Cancer Glycolysis. |
| Q64976211 | A retrospective case study of sunitinib treatment in three patients with Von Hippel-Lindau disease. |
| Q55262179 | A tightly controlled Src-YAP signaling axis determines therapeutic response to dasatinib in renal cell carcinoma. |
| Q39416850 | A unified pathogenesis for kidney diseases, including genetic diseases and cancers, by the protein-homeostasis-system hypothesis |
| Q36291365 | Actin Cytoskeletal Organization in Drosophila Germline Ring Canals Depends on Kelch Function in a Cullin-RING E3 Ligase |
| Q64376714 | Adenoviral delivery of VHL suppresses bone sarcoma cell growth through inhibition of Wnt/β-catenin signaling |
| Q123351242 | Advanced in vitro models for renal cell carcinoma therapy design |
| Q38673027 | Advances in renal genetic diagnosis |
| Q36111466 | An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC). |
| Q33906104 | Antiangiogenic activity of phthalides-enriched Angelica Sinensis extract by suppressing WSB-1/pVHL/HIF-1α/VEGF signaling in bladder cancer |
| Q91336474 | Arginine refolds, stabilizes, and restores function of mutant pVHL proteins in animal model of the VHL cancer syndrome |
| Q90453453 | Assessment of care pattern and outcome in hemangioblastoma |
| Q36274373 | Beluga whale pVHL enhances HIF-2α activity via inducing HIF-2α proteasomal degradation under hypoxia |
| Q57176537 | Bilateral Pheochromocytomas in a Patient with Y175C Von Hippel-Lindau Mutation |
| Q55370445 | Bioinformatics and functional analyses of key genes and pathways in human clear cell renal cell carcinoma. |
| Q39302546 | COSMIC: High-Resolution Cancer Genetics Using the Catalogue of Somatic Mutations in Cancer. |
| Q38746778 | Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms. |
| Q38668871 | Cabozantinib for the treatment of kidney cancer |
| Q36105139 | Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance |
| Q92677711 | Characterization of renal cell carcinoma-associated constitutional chromosome abnormalities by genome sequencing |
| Q89532702 | Checkpoint inhibitor immunotherapy in kidney cancer |
| Q58766362 | Circulating Tumor Cells for the Management of Renal Cell Carcinoma |
| Q60931664 | Clinical Syndromes and Genetic Screening Strategies of Pheochromocytoma and Paraganglioma |
| Q50285154 | Coexistence of VHL Disease and CPT2 Deficiency: A Case Report |
| Q43093361 | Computational analysis of prolyl hydroxylase domain-containing protein 2 (PHD2) mutations promoting polycythemia insurgence in humans. |
| Q26777412 | Contribution of the Type II Chaperonin, TRiC/CCT, to Oncogenesis |
| Q53263432 | Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy |
| Q60922626 | Current Landscape and the Potential Role of Hypoxia-Inducible Factors and Selenium in Clear Cell Renal Cell Carcinoma Treatment |
| Q45858755 | Cyclosporin a induces renal episodic hypoxia. |
| Q38657863 | DNMT1-maintained hypermethylation of Krüppel-like factor 5 involves in the progression of clear cell renal cell carcinoma. |
| Q42380833 | Daam2 driven degradation of VHL promotes gliomagenesis. |
| Q54969934 | Deconstructing Signaling Pathways in Cancer for Optimizing Cancer Combination Therapies. |
| Q48120175 | Decreased TGFBR3/betaglycan expression enhances the metastatic abilities of renal cell carcinoma cells through TGF-β-dependent and -independent mechanisms. |
| Q47200028 | Deletion of the von Hippel-Lindau gene in hemangioblasts causes hemangioblastoma-like lesions in murine retina |
| Q37718688 | Deubiquitinating enzyme USP20 is a positive regulator of Claspin and suppresses the malignant characteristics of gastric cancer cells |
| Q89178465 | Diagnosis and Management of Hereditary Renal Cell Cancer |
| Q90318818 | Differentiation of clear cell and non-clear cell renal cell carcinomas by all-relevant radiomics features from multiphase CT: a VHL mutation perspective |
| Q64083362 | Distinctive clinicopathological features of Von Hippel-Lindau-associated hereditary renal cell carcinoma: A single-institution study |
| Q92542015 | Dysregulation of Ketone Body Metabolism Is Associated With Poor Prognosis for Clear Cell Renal Cell Carcinoma Patients |
| Q28086796 | Dysregulation of ubiquitin ligases in cancer |
| Q49917932 | E3 Ligase VHL Promotes Group 2 Innate Lymphoid Cell Maturation and Function via Glycolysis Inhibition and Induction of Interleukin-33 Receptor. |
| Q58594889 | EZH2 Expression is increased in BAP1-mutant renal clear cell carcinoma and is related to poor prognosis |
| Q38485779 | Emerging tyrosine kinase inhibitors for the treatment of renal cancer |
| Q50969419 | Endothelial cells co-cultured with renal carcinoma cells significantly reduce RECK expression under chemical hypoxia |
| Q88985337 | Epigenetics in renal cell cancer: mechanisms and clinical applications |
| Q41574276 | Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma |
| Q30388270 | Exome-Scale Discovery of Hotspot Mutation Regions in Human Cancer Using 3D Protein Structure |
| Q30382892 | Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations. |
| Q61451235 | Expression of Tripartite Motif-Containing Proteactiin 11 (TRIM11) is Associated with the Progression of Human Prostate Cancer and is Downregulated by MicroRNA-5193 |
| Q48229920 | Expression of VHL tumor suppressor mRNA and miR-92a in papillary thyroid carcinoma and their correlation with clinical and pathological parameters. |
| Q92156808 | Fibronectin in Cancer: Friend or Foe |
| Q91728282 | Fine-tuning AKT kinase activity through direct lysine methylation |
| Q36173567 | Forkhead Transcription Factor 3a (FOXO3a) Modulates Hypoxia Signaling via Up-regulation of the von Hippel-Lindau Gene (VHL). |
| Q40979031 | Genetic alterations in Japanese extrahepatic biliary tract cancer. |
| Q33709786 | Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA |
| Q39292822 | Genetic kidney diseases: Caenorhabditis elegans as model system |
| Q45047268 | Genetics of Von Hippel-Lindau Disease. |
| Q52622727 | Genotype and phenotype correlation in von Hippel-Lindau disease based on alteration of the HIF-α binding site in VHL protein |
| Q47362904 | Genotype phenotype correlation in Asian Indian von Hippel-Lindau (VHL) syndrome patients with pheochromocytoma/paraganglioma |
| Q36083146 | Genotype-phenotype analysis of von Hippel-Lindau syndrome in Korean families: HIF-α binding site missense mutations elevate age-specific risk for CNS hemangioblastoma |
| Q64081971 | Genotype-phenotype relations of the von Hippel-Lindau tumor suppressor inferred from a large-scale analysis of disease mutations and interactors |
| Q50227566 | Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression |
| Q92257354 | Glutathione Metabolism in Renal Cell Carcinoma Progression and Implications for Therapies |
| Q36099567 | HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma |
| Q38431622 | HIF prolyl hydroxylase PHD3 regulates translational machinery and glucose metabolism in clear cell renal cell carcinoma |
| Q38666170 | HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond |
| Q100464172 | HIF-2α is indispensable for regulatory T cell function |
| Q55083786 | Hereditary Renal Tumor Syndromes: Update on Diagnosis and Management. |
| Q52572027 | Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management. |
| Q53312284 | Hereditary tumor syndromes in neuropathology |
| Q42217007 | Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation. |
| Q26786759 | Hyperplasia in glands with hormone excess |
| Q55419613 | Hypoxia-Inducible Factor 2-Dependent Pathways Driving Von Hippel-Lindau-Deficient Renal Cancer. |
| Q36342313 | Hypoxia-inducible factor-2α stabilizes the von Hippel-Lindau (VHL) disease suppressor, Myb-related protein 2 |
| Q40462478 | Identification and validation of an eight-gene expression signature for predicting high Fuhrman grade renal cell carcinoma. |
| Q59129654 | Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer |
| Q50159013 | In-silico VHL Gene Mutation Analysis and Prognosis of Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease. |
| Q36161809 | Inactivation of the tumor suppressor gene von Hippel-Lindau (VHL) in granulocytes contributes to development of liver hemangiomas in a mouse model |
| Q101407728 | Increased chromosomal instability characterizes metastatic renal cell carcinoma |
| Q39395931 | Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potential |
| Q53435219 | Integrated genomic analysis identifies clinically relevant subtypes of renal clear cell carcinoma |
| Q64093013 | Intra-Familial Phenotypic Heterogeneity and Telomere Abnormality in von Hippel- Lindau Disease: Implications for Personalized Surveillance Plan and Pathogenesis of VHL-Associated Tumors |
| Q91876542 | Investigation of the role of VHL-HIF signaling in DNA repair and apoptosis in zebrafish |
| Q41247181 | Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight |
| Q38889283 | Key considerations in the treatment of von Hippel-Lindau disease |
| Q42086368 | Link between dysregulated hypoxia signaling and aberrant methylation in clear cell renal cell carcinoma? |
| Q38819629 | Long-term follow-up and clinical course of a rare case of von Hippel-Lindau disease: A case report and review of the literature |
| Q91874588 | Loss of ELF5-FBXW7 stabilizes IFNGR1 to promote the growth and metastasis of triple-negative breast cancer through interferon-γ signalling |
| Q47117026 | Loss of PBRM1 rescues VHL dependent replication stress to promote renal carcinogenesis |
| Q30275713 | Loss of Quiescence in von Hippel-Lindau Hemangioblastomas is Associated with Erythropoietin Signaling |
| Q39229171 | Mammalian SWI/SNF complexes in cancer: emerging therapeutic opportunities |
| Q37217474 | Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin. |
| Q28073174 | Medical treatment of renal cancer: new horizons |
| Q91791256 | Meloxicam, a Selective COX-2 Inhibitor, Mediates Hypoxia-Inducible Factor- (HIF-) 1α Signaling in Hepatocellular Carcinoma |
| Q39340415 | Metabolic Alterations in Cancer and Their Potential as Therapeutic Targets |
| Q64097631 | Metabolic profiling of cancer cells reveals genome-wide crosstalk between transcriptional regulators and metabolism |
| Q38698512 | Metastatic renal cell carcinoma without evidence of a renal primary |
| Q51158837 | MicroRNAs in clear cell renal cell carcinoma: biological functions and applications |
| Q59791159 | Modeling epigenetic modifications in renal development and disease with organoids and genome editing |
| Q38697094 | Multiple renal cancer susceptibility polymorphisms modulate the HIF pathway. |
| Q90006920 | Muscleblind-like 2 controls the hypoxia response of cancer cells |
| Q59793924 | Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity |
| Q58573422 | Never-in-mitosis A-related kinase 8, a novel target of von-Hippel-Lindau tumor suppressor protein, promotes gastric cancer cell proliferation |
| Q90139170 | New Insights Into Pheochromocytoma Surveillance of Young Patients With VHL Missense Mutations |
| Q58103553 | Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy |
| Q91863036 | Novel gene mutation in von Hippel-Lindau disease - a report of two cases |
| Q55516484 | Novel genotype-phenotype correlations in five Chinese families with Von Hippel-Lindau disease. |
| Q57822415 | Oncometabolite induced primary cilia loss in pheochromocytoma |
| Q52686884 | Overexpression of COPS3 promotes clear cell renal cell carcinoma progression via regulation of Phospho-AKT(Thr308), Cyclin D1 and Caspase-3. |
| Q90404451 | Oxygen Tension and the VHL-Hif1α Pathway Determine Onset of Neuronal Polarization and Cerebellar Germinal Zone Exit |
| Q35995926 | PBRM1 Regulates the Expression of Genes Involved in Metabolism and Cell Adhesion in Renal Clear Cell Carcinoma |
| Q47370222 | PBRM1 and VHL expression correlate in human clear cell renal cell carcinoma with differential association with patient's overall survival |
| Q38805814 | Parkin modulates expression of HIF-1α and HIF-3α during hypoxia in gliobastoma-derived cell lines in vitro |
| Q98647386 | Pathogenic germline variants in patients with features of hereditary renal cell carcinoma: evidence for further locus heterogeneity |
| Q38542150 | Pheochromocytoma: Gasping for Air. |
| Q47115530 | Phosphorylation and Ubiquitination Regulate Protein Phosphatase 5 Activity and Its Prosurvival Role in Kidney Cancer |
| Q38786652 | Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function |
| Q54977962 | Pilot study of dovitinib in patients with von Hippel-Lindau disease. |
| Q28822022 | Potent and selective chemical probe of hypoxic signalling downstream of HIF-α hydroxylation via VHL inhibition |
| Q38970282 | Precision medicine from the renal cancer genome |
| Q39095254 | Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review |
| Q91574563 | Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment |
| Q47097655 | Proteome profiling of clear cell renal cell carcinoma in von Hippel-Lindau patients highlights upregulation of Xaa-Pro aminopeptidase-1, an anti-proliferative and anti-migratory exoprotease. |
| Q36003500 | Proteotranscriptomic Analysis Reveals Stage Specific Changes in the Molecular Landscape of Clear-Cell Renal Cell Carcinoma |
| Q33292271 | RalBP1 and p19-VHL play an oncogenic role, and p30-VHL plays a tumor suppressor role during the blebbishield emergency program |
| Q90716279 | Rb1/Rbl1/Vhl loss induces mouse subretinal angiomatous proliferation and hemangioblastoma |
| Q37598376 | Reduction of hepatic fibrosis by overexpression of von Hippel-Lindau protein in experimental models of chronic liver disease |
| Q38404984 | Regulation of hypoxia responses by flavin adenine dinucleotide-dependent modulation of HIF-1α protein stability |
| Q50941188 | Renal cancer. |
| Q35610555 | Repression of hypoxia-inducible factor α signaling by Set7-mediated methylation |
| Q89461828 | Retinal haemangioblastomas in von Hippel-Lindau germline mutation carriers: progression, complications and treatment outcome |
| Q132042932 | Ribosomal Protein S6: A Potential Therapeutic Target against Cancer? |
| Q37701667 | Role of VHL, HIF1A and SDH on the expression of miR-210: Implications for tumoral pseudo-hypoxic fate. |
| Q37697020 | SENP1 promotes proliferation of clear cell renal cell carcinoma through activation of glycolysis |
| Q60921421 | SENP1-mediated deSUMOylation of USP28 regulated HIF-1α accumulation and activation during hypoxia response |
| Q38824719 | Safety of available treatment options for renal cell carcinoma |
| Q26744089 | Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective |
| Q92969786 | Sex specific associations in genome wide association analysis of renal cell carcinoma |
| Q38646901 | Shorter telomere length increases age-related tumor risks in von Hippel-Lindau disease patients. |
| Q42434480 | Signs and genetics of rare cancer syndromes with gastroenterological features |
| Q55023971 | Single-cell genetic analysis validates cytopathological identification of circulating cancer cells in patients with clear cell renal cell carcinoma. |
| Q47884990 | Specific Localization of Missense Mutations in the VHL Gene in Clear Cell Renal Cell Carcinoma |
| Q38828242 | Structure, function and regulation of jade family PHD finger 1 (JADE1). |
| Q92372125 | Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell Carcinoma |
| Q99608172 | TET is targeted for proteasomal degradation by the PHD-pVHL pathway to reduce DNA hydroxymethylation |
| Q37699330 | TRIM11, a direct target of miR-24-3p, promotes cell proliferation and inhibits apoptosis in colon cancer |
| Q100455154 | Targeting the HIF2-VEGF axis in renal cell carcinoma |
| Q38668940 | Targeting the RhoGTPase/ROCK pathway for the treatment of VHL/HIF pathway-driven cancers. |
| Q54112866 | Targeting the mevalonate pathway suppresses VHL-deficient CC-RCC through a HIF-dependent mechanism. |
| Q38601568 | Targeting tumor suppressor genes for cancer therapy |
| Q93102798 | The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell Carcinoma |
| Q92254395 | The E3 ligase VHL promotes follicular helper T cell differentiation via glycolytic-epigenetic control |
| Q38672574 | The Elephant in the Room: The Role of Microtubules in Cancer |
| Q50026055 | The HIF and other quandaries in VHL disease |
| Q51091490 | The epigenetic landscape of clear-cell renal cell carcinoma |
| Q39021700 | The epigenetic landscape of renal cancer |
| Q28079015 | The ever-expanding role of HIF in tumour and stromal biology |
| Q57903458 | The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma |
| Q37109549 | The multifaceted role of autophagy in tumor evasion from immune surveillance |
| Q51767200 | The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma |
| Q91809745 | The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease |
| Q38871343 | Therapeutic Strategies for Hereditary Kidney Cancer |
| Q26796702 | Therapeutic challenges in renal cell carcinoma |
| Q90353766 | Therapies targeting the signal pathways of pheochromocytoma and paraganglioma |
| Q39257898 | Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA H1047R in HER2/ER-positive breast cancer |
| Q37645058 | USP9X destabilizes pVHL and promotes cell proliferation |
| Q46609299 | Ubiquitin ligases in oncogenic transformation and cancer therapy |
| Q103825405 | Ultrasound Microbubble-Mediated VHL Regulates the Biological Behavior of Ovarian Cancer Cells |
| Q92060302 | Upregulation of miR-211 Promotes Chondrosarcoma Development via Targeting Tumor Suppressor VHL |
| Q54943750 | VHL and Hypoxia Signaling: Beyond HIF in Cancer. |
| Q33826897 | VHL deficiency augments anthracycline sensitivity of clear cell renal cell carcinomas by down-regulating ALDH2. |
| Q38714947 | VHL promotes immune response against renal cell carcinoma via NF-κB-dependent regulation of VCAM-1. |
| Q37166626 | VHLdb: A database of von Hippel-Lindau protein interactors and mutations |
| Q50278297 | Vascular Endothelial (VE)-Cadherin, Endothelial Adherens Junctions, and Vascular Disease |
| Q89868243 | Von Hippel-Lindau Disease and the Eye |
| Q55110633 | Von Hippel-Lindau Disease. |
| Q51738941 | Von Hippel-Lindau mutations disrupt vascular patterning and maturation via Notch. |
| Q42378385 | Von Hippel-Lindau regulates interleukin-32β stability in ovarian cancer cells. |
| Q36286769 | WSB1 promotes tumor metastasis by inducing pVHL degradation |
| Q91980552 | Whole-exome sequencing and immunohistochemistry findings in von Hippel-Lindau disease |
| Q26744312 | Wnt Signaling in Renal Cell Carcinoma |
| Q94550232 | ZHX2 drives cell growth and migration via activating MEK/ERK signal and induces Sunitinib resistance by regulating the autophagy in clear cell Renal Cell Carcinoma |
| Q37666827 | pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner |
| Q89967141 | von Hippel-Lindau Syndrome: Genetic Study of Case With a Rare Pathogenic Variant With Optic Nerve Hemangioblastoma, a Rare Phenotypic Expression |
Search more.